Mankind Pharma Limited Receives Order from Office of Commissioner of Central Tax, Central Excise and Service Tax, Secunderabad GST Commissionerate GST Bhawan, Hyderabad
April 26, 2024 at 09:35 am EDT
Share
Mankind Pharma Limited announced that the Company has received an Order from Office of Commissioner of Central Tax, Central Excise and Service tax, Secunderabad GST Commissionerate GST Bhawan, Hyderabad ("Department") dated April 25, 2024 received on April 26, 2024 imposing a penalty of INR 2,452,328/- under applicable provisions of the CGST Act, 2017. The Company is examining the aforesaid Order received from the Department and shall take appropriate steps, including filing of an appeal. There is no material impact on financials, operations or other activities of the Company.
Mankind Pharma Limited is an India-based pharmaceutical company. The Company is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It has a portfolio of formulations in several therapeutic areas, such as anti-infectives, cardiovascular, gastrointestinal, vitamins/minerals/nutrients, respiratory, anti-diabetic, dermatology, gynecology, and pain/analgesics, among others. Its other therapeutic areas include urology, ophthalmology, antiparasitic, stomatological, antineoplastic/immunomodulator, hepatoprotective, anti-malarial, blood-related, hormones, antiviral, sex stimulants/rejuvenators, anti-tuberculosis, parenteral and vaccines. Its portfolio of brands includes Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, and others.
Mankind Pharma Limited Receives Order from Office of Commissioner of Central Tax, Central Excise and Service Tax, Secunderabad GST Commissionerate GST Bhawan, Hyderabad
MANKIND PHARMA LIMITED 
